Belize
Tuberculosis profile
| High HIV burden |
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.014 (0.014–0.014) 4.3 (4.3–4.3)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 1.7 (1.5–2.1)
Prevalence  (includes HIV+TB) 0.17 (0.071–0.3) 51 (22–92)
Incidence  (includes HIV+TB) 0.13 (0.11–0.16) 40 (33–48)
Incidence (HIV+TB only) 0.026 (0.021–0.032) 8.1 (6.6–9.7)
Case detection, all forms (%) 65 (54–79)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 36 (47) Relapse 7 (100)
Smear-negative 14 (18) Treatment after failure 0 (0)
Smear-unknown / not done 22 (29) Treatment after default 0 (0)
Extrapulmonary 5 (6) Other 0 (0)
Other 0 (0)      
Total new 77   Total retreatment 7  
           
Other (history unknown) 0        
Total new and relapse 84   Total cases notified 84  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.5 2.4 1.5
Age < 15 1 1 0
Laboratories 2012
Smear (per 100 000 population) 0.9
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? Yes, outside
country
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive     Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary    
Retreatment    
TB/HIV 2012 Number (%)
TB patients with known HIV status 68 (81)
HIV-positive TB patients 19 (28)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 19 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 2.2 (1.4–3.1) 14 (4.6–23)
MDR-TB cases among notified pulmonary
TB cases
2 (1–2) 1 (0–2)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed MDR-TB cases 0 0 0
Patients started on MDR-TB treatment     0
Financing TB control 2013
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-19 Data: www.who.int/tb/data